The companies look set to join Lilly and Regeneron once an EUA is secured, but producing enough supplies to meet demand will be the next challenge.
Vir Biotechnology and GlaxoSmithKline have recorded a major success with VIR-7831, which has shown an 85% lower risk of hospitalization or death in COVID-19 patients receiving the antibody therapy.
The companies said they would now prepare to file the results from the Phase III COMET ICE trial with the...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
